Tagged with J&J

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma Despite the already existing efficiencies in the Italian healthcare system, there is still significant room for improvement. Johnson & Johnson Medical’s head for southern Europe discusses a number of opportunities where the company can help to improve healthcare quality while reducing costs holistically. Given Italy’s current healthcare sustainability concerns, what…

pharma Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s future in Turkey. As an introduction for our readers, Ozgur, can you please give an overview of where J&J Turkey…

J&J The future of healthcare calls for all stakeholders to partner up. The general manager for Johnson & Johnson (J&J) Medical in Mexico shares his view about the challenges the healthcare system is facing and his vision about how to transform J&J from being merely a supplier of products to becoming…

Janssen Eric Alvarez, managing director of Janssen Mexico, explains why it is important to distinguish between the public and private sector when discussing the latest developments in the pharmaceutical industry, and notes how the mindset within the government is beginning to change, seeing investing in healthcare as an investment in the…